Latest News and Press Releases

New analysis from Phase 3 CEPHEUS study demonstrates 85 percent of patients who achieved MRD negativity (10-6) with daratumumab SC were progression free at 4.5 years1 AURIGA study shows higher rates...

100 percent of evaluable patients for minimal residual disease (MRD) testing achieved MRD negativity in MajesTEC-5 as induction therapy and MajesTEC-4 as maintenance therapy1,2 BEERSE, BELGIUM, Dec. ...

First subcutaneous anti-CD38 therapy to demonstrate potential to prevent end-organ damage, and extend progression-free survival and overall survival based on findings from Phase 3 AQUILA study1 ...

Bei Erwachsenen mit mäßig bis schwer aktivem Sjögren-Syndrom, die mit dem FcRn-Blocker Nipocalimab behandelt wurden, zeigte sich nach 24 Wochen eine Verbesserung der Krankheitsaktivität mit einer...

L’association amivantamab plus lazertinib présente le potentiel de devenir la nouvelle norme de soins en tant qu’option de traitement de première intention des patients adultes atteints d’un CPNPC...

Das Kombinationsschema aus amivantamab plus lazertinib bietet das Potenzial, einen neuen Behandlungsstandard als Erstlinienoption für erwachsene Patienten mit fortgeschrittenem NSCLC mit EGFR ex19del-...

The amivantamab plus lazertinib combination regimen offers potential to provide new standard of care as first-line option for adult patients with advanced NSCLC with EGFR ex19del or L858R substitution...

Adults with moderately-to-severely active Sjögren’s disease who received investigational FcRn blocker, nipocalimab, had improvements in disease activity scores at 24 weeks with accompanying...

En cas d’obtention de l’autorisation, le daratumumab deviendra la première option thérapeutique pour les patients atteints d’un myélome multiple indolent et présentant un risque élevé de développer un...

Se approvato, daratumumab diventerà la prima opzione terapeutica per i pazienti con mieloma multiplo smouldering che hanno un alto rischio di sviluppare il mieloma multiplo, offrendo un approccio...